DRUG DEVELOPMENT WITH AI
These large-, mid- and small-cap stocks have upside potential of more than 20% in 1 year, according to analysts
The probability of a sharp, damaging downturn now appears low, and the broad direction favours the market. So, the stance should be the same as in these past few weeks: Shedding fear, but cautiously optimistic. Focus on the business under the stock you are interested in, and keep one eye on what is happening globally.
Jensen Huang quits as CEO of Nvidia: He was once caught getting cosy with Nvidia VP on camera. Who is Kimberly Powell, the second woman he has been linked with?
Nvidia founder Jensen Huang resigned as CEO on Thursday following reports of an affair with Kimberly Powell, the company’s vice president of healthcare. This follows reports that the billionaire was involved in an affair with Alice Huang, a Chinese executive who U.S. intelligence asserted was a spy for Beijing.
Before Nvidia, Kimberly Powell was an engineering intern in radiology tech; How she built an 18-year career in AI healthcare, now in the spotlight after Jensen Huang report
Kimberly Powell did not begin her career in AI drug discovery. She started as an engineering intern, working with radiologists and medical imaging technology. That experience eventually brought her to Nvidia, where she spent 18 years building its healthcare business. Now, a report about her alleged relationship with Jensen Huang has put her in the headlines. But how did she go from working in radiology to becoming one of Nvidia's senior executives?
What will happen to Kimberly Powell after Jensen Huang's resignation from Nvidia?
The resignation of Jensen Huang from Nvidia has cast shadows over Kimberly Powell's position in the company. Allegations arise suggesting that both individuals had extramarital affairs, complicating the narrative. Huang admitted to infidelity but refrained from naming anyone, while Powell, an 18-year Nvidia veteran who heads the healthcare division and supports AI in medicine, faces uncertainty. Nvidia remains silent on her job's future amidst this controversy.
Jensen Huang quits as Nvidia CEO, putting $4 trillion empire in transition
Jensen Huang has resigned as CEO of Nvidia, prompting concerns regarding the company’s future direction. Colette Kress has been appointed as interim CEO while the board searches for a permanent successor. Huang's departure follows controversy related to personal relationships and an investigation into potential foreign intelligence targeting. His hands-on management style has significantly influenced Nvidia's operations over the decades.
Colette Kress for now, but who next? Inside the race to become only the second CEO in Nvidia’s history
As Jensen Huang steps down as Nvidia CEO following two controversies involving his reported relationships with two women, the question is, "who will lead the AI chipmaker next?" Nvidia has named CFO Colette Kress as interim CEO, but who could get the job permanently? From Ian Buck to Rene Haas, several names are now in the succession discussion. Here is the story behind the new race to become only the second CEO in Nvidia’s history.
- Go To Page 1
From medical imaging to AI drug discovery: The 18-year Nvidia career of Kimberly Powell, now in the spotlight after Jensen Huang relationship report
Kimberly Powell joined Nvidia in 2008 to promote its chips for medical imaging. She became vice president of healthcare in 2017 and now oversees technology for medical imaging, life sciences and drug discovery. A New York Times report alleging an intimate relationship with CEO Jensen Huang has shifted attention to her long career and their workplace relationship.
Nvidia CEO crisis: Who is Jay Puri? Longtime Nvidia VP in focus as Jensen Huang faces scrutiny over alleged affairs with Alice Huang and Kimberly Powell
Nvidia CEO replacement Jay Puri: Jay Puri, an Indian-origin executive who spent more than two decades at Nvidia, is drawing attention as CEO Jensen Huang faces reports of a possible board ouster. Puri retired from his executive role in August 2026, but his experience at the chipmaker has brought his career into focus amid leadership uncertainty.
Watch: Jensen Huang’s reported extramarital partner Kimberly Powell walks the show floor in NVIDIA video
During her talk at BIO 2026, Kimberly Powell of NVIDIA showcased exciting advancements in AI and healthcare technology. Yet, the spotlight has shifted as reports of a claimed affair with CEO Jensen Huang emerged, who recently acknowledged his infidelity, impacting his family. Concurrent investigations are exploring links to foreign intelligence, and NVIDIA assures a thorough and transparent approach to these weighty accusations.
Musk wants to hire Jensen Huang: Elon Musk says he would be honoured to recruit Nvidia CEO if board decides to replace him
Musk hiring Jensen Huang: Elon Musk has said he would be honoured to hire Nvidia CEO Jensen Huang if the chipmaker's board removes him. The comment followed reports of two alleged extramarital relationships involving Huang, including one with Nvidia executive Kimberly Powell and another with a Chinese woman suspected by US intelligence officials of spying for China.
Who is Kimberly Powell? Nvidia vice president who had extramarital affair with CEO Jensen Huang allegedly
Kimberly Powell, Nvidia's vice president of healthcare, has been named in a New York Times report alleging that CEO Jensen Huang had an extramarital relationship with her. Powell joined Nvidia in 2008 and now leads its worldwide healthcare business, covering AI, medical imaging, life sciences and drug discovery.
Stocks in news: Tata Power, Cupid, Garden Reach, ITC, Aurobindo Pharma and Vodafone Idea
Indian benchmark indices have extended their winning streak, closing positively after the Muhurat trading session. Key stocks such as life insurance companies and Tata Power reported notable quarterly earnings results. HDFC Life and LIC showed healthy premium growth, while Tata Power recorded a record profit in Q2 FY27. Other companies like Cupid and Mishra Dhatu Nigam also reported impressive profit increases during the quarter.
Dario Amodei says AI could make cancer, Alzheimer’s ‘relics of the past’ in less than a decade as Anthropic expands AI-driven drug discovery push
Anthropic is collaborating with several pharmaceutical companies to utilize AI in drug development processes. These partnerships aim to improve the efficiency of drug discovery, addressing complex challenges in medical research. Notable projects include redesigning therapeutic molecules and accelerating antibody designs for various diseases. Anthropic has also initiated its own research on rare childhood muscular dystrophies, targeting potential clinical trials by late 2028.
Drugmakers tap China AI app boom to reach doctors as crackdown upends marketing
As scrutiny intensifies, Chinese pharmaceutical companies are shifting gears toward digital marketing initiatives. Traditional face-to-face communications are waning, prompting the industry to embrace AI-fueled applications for connecting with healthcare providers. These tools facilitate compliant relationships, sparking partnerships among health-tech firms to disseminate clinical information through digital channels. This marks a pivotal change in marketing dynamics within the pharmaceutical landscape.
How Nvidia CEO Jensen Huang's extramarital affair could cause collateral damage in Washington
The affair between Nvidia CEO Jensen Huang and a Chinese businesswoman suspected of spying for Beijing has triggered investigations in the US, raising concerns over national security and the security of sensitive AI technology. The controversy has drawn scrutiny from Congress, the Justice Department and Nvidia's board, with President Donald Trump also weighing in.
Anthropic targets $90 billion IPO at $1.4 trillion valuation
Anthropic PBC is preparing for an initial public offering aiming for a fully diluted valuation of $1.4 trillion. The company plans to raise up to $90.4 billion, including a private placement with major investors. It has reported a revenue run rate of $81 billion, showcasing significant growth in recent months. The IPO is scheduled to price on November 18 and begin trading the next day.
Pharma industry steps up API investments to cut import dependence, move up value chain
India's pharmaceutical sector is shifting towards high-value medicines and reducing reliance on imports through local manufacturing. Investments in active pharmaceutical ingredients and advanced therapies are on the rise to meet new healthcare demands. Industry leaders highlight the significance of supply-chain resilience and advancements in manufacturing capabilities. Recent data indicates strong domestic market growth and increasing pharmaceutical exports.
AI investment cycle may have peaked, Jefferies warns; raises India allocation to 14%
According to a recent Jefferies report, global investment in artificial intelligence appears to be facing a mid-cycle correction. Although US tech giants have ramped up their capital spending, there are growing concerns regarding both financing and profitability. This situation may adversely impact US economic growth. Investors are advised to explore opportunities outside the AI realm, especially in healthcare and biotechnology sectors.
Arunoday Singh-headed O-Health secures strategic funding
O-Health has received strategic funding from several investors to advance its healthcare technology solutions. The company aims to enhance its voice-first AI-enabled clinical pre-assessment platform for better patient information management. The investment will support the expansion into additional healthcare sectors and development of indigenous AI models and clinical hardware. O-Health plans to broaden its focus to include preventive health technologies and intelligent hospital workflows.
OpenAI to acquire developer tools firm Pierre to expand Codex capabilities
OpenAI will acquire Pierre Computer Company, the developer of open-source coding tools, to expand its Codex platform's capabilities in building, understanding and reviewing software, as it looks to strengthen the role of AI agents across the software development process.
Democrats took Capitol Hill. Trump still has a Veto. What happens next and who can make their case for 2028?
Democrats are set to take control of the House and Senate after the 2026 midterm elections. President Donald Trump still has the power to veto their bills. This could be a test for Democats on how they handle that power and bring policies which could shape their pitch to voters in 2028.
With most drug candidates failing in humans, India’s draft rules bet on the wrong science in animal lab testing
Recent draft rules in India threaten advancements in non-animal testing for drug development and safety. The new regulations may prioritize animal testing over innovative human-based methods, despite their proven reliability. Efforts to incorporate non-animal methodologies into national standards have gained support from various government initiatives. Significant funding has been allocated to promote alternative testing methods throughout the country.
His grandfather died of pancreatic cancer: This Hyderabad startup founder is using AI to develop a personalised cancer vaccines
Hyderabad-based biotech startup PopVax, founded by Soham Sankaran, is developing AI-powered personalised cancer vaccines using mRNA technology. Inspired partly by his family's experience with pancreatic cancer, he aims to help the immune system identify and attack cancer cells using treatments designed around individual patients' tumour genetics.
American companies brace for a pivot as US midterm elections get underway
US midterms: Corporate America is anticipating a potential shifts in Washington's power dynamics. Analysts predict that a strong Democratic showing could benefit sectors such as clean energy, housing and healthcare. Conversely, AI and defence stocks may face increased scrutiny from lawmakers.
Hospital balance sheet: How AI could cut costs and improve efficiency
As hospitals grapple with soaring costs in drugs, supplies, and labor, the integration of AI emerges as a vital necessity.
AI is no longer just coding or generating images. It has now designed a virus that was used on a human being. Did the patient survive?
A California startup has used artificial intelligence to design a virus that was administered to a human patient for the first time. The experimental treatment uses bacteriophages to target antibiotic-resistant bacteria, potentially opening a new way to fight infections that conventional medicines cannot control. However, the patient's recovery has not been disclosed.
Anthropic's Claude cut Enveda's drug records' review time by 89%
Colorado-based biotechnology company Enveda developed a CMC Document Processor to help reviewers identify errors, inconsistencies and potential quality issues across these records.
Swiss AI drug trial startup receives funding from Spotify-backer Creandum
An AI foundation model, trained on about two million human RNA readouts, would replace these and animal testing with 12-week simulations, the company said.
AI halves drug discovery times, but =trial bottleneck remains a costly reality
Novo Nordisk, Sanofi and Dr Reddy’s Laboratories are among the companies exploring applications ranging from drug discovery to laboratory automation and research.
Load More
